Quick Telecast
Expect News First

Piper sees GLP-1s increasing demand for knee/hip surgeries near-term (NYSE:NVO)

0 128


Mohammed Haneefa Nizamudeen/iStock via Getty Images

Piper Sandler said it expects upcoming results from a Novo Nordisk (NVO) study of its weight-loss drug semaglutide in the treatment of osteoarthritis to be “mediocre” and demand for knee and hip replacements to increase near-term as more patients qualify for


Human knee replacement surgery. Knee joint treatment. Knee injury. 3d illustration

Mohammed Haneefa Nizamudeen/iStock via Getty Images

Piper Sandler said it expects upcoming results from a Novo Nordisk (NVO) study of its weight-loss drug semaglutide in the treatment of osteoarthritis to be “mediocre” and demand for knee and hip replacements to increase near-term as more patients qualify for

FOLLOW US ON GOOGLE NEWS

Read original article here

Denial of responsibility! Quick Telecast is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials, please contact us by email – [email protected]. The content will be deleted within 24 hours.

Leave a comment
Ads Blocker Image Powered by Code Help Pro

Ads Blocker Detected!!!

We have detected that you are using extensions to block ads. Please support us by disabling these ads blocker.

buy kamagra buy kamagra online